# S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor

> **NCT00068367** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 24 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** erlotinib hydrochloride

## Key facts

- **NCT ID:** NCT00068367
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2007-07
- **Final completion:** 2009-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00068367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00068367, "S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00068367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*